Review Article
Novel Therapies for Aggressive B-Cell Lymphoma
Table 4
Immunomodulatory agents in clinical development for the treatment of aggressive NHL. [B: bortezomib; CR: complete response; CRR: complete response rate; CRu: unconfirmed CR; Dex: dexamethasone; MCL: mantle cell lymphoma; mDR: median duration of response; mEFS: median event-free survival; MOA: mechanism of action; mPFS: median progression-free survival; NHL: non-Hodgkin lymphoma; ORR: overall response rate; OS: overall survival; PR: partial response; R: rituximab; R-CHOP21: cyclophosphamide, doxorubicin, vincristine, prednisolone plus rituximab, every 21 days; R/R: relapsed or refractory; TTF: time to treatment failure.]
| | Drug | MOA (target) | Eligibility | Phase | Randomized | Results |
| | Thalidomide [111] | Immunomodulator | R/R MCL (alone, with R, with B, with RB, with other agents) | NA | No | ORR: 50%; CR: 20.7; 2-year TTF rate: 10.9%; 2-year OS rate: 49.6% | | Lenalidomide [113] | Immunomodulator | R/R aggressive NHL | II | No | ORR: 35%; CR/CRu: 12%; mDR: 6.2 months; mPFS: 4.0 months | | Lenalidomide [114] | Immunomodulator | R/R aggressive NHL | II | No | ORR: 35%; CR/CRu: 13%; mPFS: 3.5 months | | Lenalidomide [116] | Immunomodulator | R/R MCL | II | No | ORR: 53%; CR: 20%; mPFS: 5.6 months | | Lenalidomide [117] | Immunomodulator | R/R MCL (with Dex) | II | No | ORR: 55%; CR: 24% | | Lenalidomide [118] | Immunomodulator | R/R MCL (with R) | I/II | Dose-finding | ORR: 53%; CRR: 31%; mPFS: 14.0 months | | Lenalidomide [120] | Immunomodulator | R/R Indolent or MCL (with R/Dex) | II | No | ORR: 57%; mEFS: 12.0 months; 78% | | Lenalidomide [121] | Immunomodulator | Previously untreated DLBCL (with R-CHOP21) | I/II | Dose-finding | CR: 15/21; PR: 1/21 |
|
|
